Business ❯ Finance ❯ Corporate Acquisitions
Gilead Sciences Biotech Firms Novo Nordisk Mergers and Acquisitions
The cash deal is expected to trim Gilead’s 2025 EPS by about $0.23–$0.25 as closing awaits regulatory approval.
